---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-320150"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:05:42.536279+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M

## Summary
- Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.
- The deal value is up to $315 million; Nuvalent is not a party to the transaction.
- Nuvalent clarifies the 'low single digit preexisting royalty' is exactly 1.5% of net sales of both candidates.
- Nuvalent's revenue share agreement with its scientific founder remains unchanged.

## SEC filing metadata
- accession: 0001193125-25-320150
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/0001193125-25-320150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/d53736d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-320150
- JSON: https://secwatch.observer/filing/0001193125-25-320150.json
- Plain text: https://secwatch.observer/filing/0001193125-25-320150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.